It's Not Easy Being Green
This article was originally published in SRA
Executive Summary
“The mere presence of a [pharmaceutical] substance in water does not mean harm will result.” Over the past several months, there has been increasing pressure on the pharmaceutical industry and regulators to verify this statement made by Alan Goldhammer, US industry association PhRMA's deputy vice president, regulatory affairs, at a congressional hearing in April1. A subcommittee of the Senate Environment and Public Works Committee held the hearing a month after media reports revealed that traces of various drugs were found in the drinking water of 24 major US metropolitan areas - resulting in demands for new reassurances about the safety of drugs, albeit in a very different context than usual2.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.